TIGIT and neoplasm: In response to therapy with antibodies targeting PD-1, an increase in the expression of TIGIT ligands by tumor cells has been shown [126], which probably reflects adaptive processes in tumor cells and explains the high antitumor efficacy of the joint use of blocking antibodies.